Loading...
| A14002 | Pages: NA | Dec 2021 | 64 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Huntington’s Disease Genetic Testing Market
Request Now !Currently, only two symptom-alleviating therapies are specifically approved for this disorder, which include Austedo and Xenazine. Early signs and symptoms can include depression, irritability, poor coordination, small involuntary movements, and trouble learning new information or making decisions. Huntington's disease is caused by mutations in the Huntington (HTT) gene. The Huntington (HTT) gene provides instructions for making a protein called huntingtin. Even though the function of this protein is unclear, it appears to play a vital role in brain nerve cells (neurons). A DNA fragment known as a cytosine–adenine–guanine (CAG) trinucleotide repeat is involved in the HTT mutation that causes Huntington's disorder. The test can be done by sending blood samples to a laboratory, which can be used to detect the gene and confirm the diagnosis, as well as for presymptomatic testing of carriers and high-risk candidates and prenatal testing.
Market Scope and Structure Analysis
Report Metric | Details |
Market Size Available for Years | 2020–2030 |
Base Year Considered | 2020 |
Forecast Period | 2021–2030 |
Forecast Unit | Value (USD) |
Segments Covered | Product ,Type, Application, and Region |
Regions Covered | North America, Europe, Asia-Pacific, and LAMEA |
Companies Covered |
Laboratory Corporation of America Holdings, Quest Diagnostics Inc., EGL Genetic Diagnostics LLC., Cooper Genomics Inc., Blueprint Genetics Oy, CeGaT GmbH, Centogene N.V., Variantyx Inc., and Asuragen Inc. |
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
In the early phase of COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global market. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.
Owing to such factors, COVID 19 is expected to have a significant impact Huntington’s disease genetic testing market.
Top Impacting Factors
Increasing prevalence of genetic diseases and increase in geriatric population fueled the growth of the market.
In addition, with increasing number of initiatives by public and private organizations to increase the awareness regarding the disease, the Huntington’s disease genetic testing market is witnessing significant growth.
Furthermore, increasing in focus of researchers on developing new technologies and rising research on genetic disorders are expected to propel the growth of the market.
Rising healthcare expenditure, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the market.
However, lack of knowledge regarding Huntington’s disease and its diagnosis is expected to restrain the market growth.
Market Trends
New Product Launches to Flourish the Market
In January 2019, Asuragen Inc., a company that offers genetic testing services, announced the commercialization of the AmplideX Huntington (HTT) kit, which detects cytosine–adenine–guanine (CAG) trinucleotide repeats within the Huntington (HTT) gene, which are aberrations associated with HD.
In February 2020, CaGaT GmbH launched CeGaT Exome Xtra, a genetic diagnostic tool for patients with complex, unspecific, and rare diseases.
Key Segments Covered
Segment | Subsegment |
Patient Gender |
|
Patient Group |
|
Region |
|
Key Benefits of the Report
Questions Answered in the Huntington’s Disease Genetic Testing Market Report
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
